E0 ConsensusModerate confidencePEM ?Review-NarrativePeer-reviewedMachine draft
Myalgic Encephalomyelitis: Symptoms and Biomarkers.
Jason, Leonard A, Zinn, Marcie L, Zinn, Mark A · Current neuropharmacology · 2015 · DOI
Quick Summary
This review article examines what we know about ME/CFS symptoms and biological markers that could help diagnose the disease. The authors point out that ME/CFS is often confused with other conditions like early multiple sclerosis or Parkinson's disease because they share similar symptoms. They call for better standardized ways to diagnose ME/CFS and more large-scale studies to understand what's happening in the body during this illness.
Why It Matters
This systematic review is important because it clarifies why ME/CFS diagnosis remains challenging and identifies practical areas where better biomarkers and standardized diagnostic approaches could improve patient outcomes. For researchers, it highlights critical gaps in the evidence base and provides a roadmap for future investigation that could lead to faster, more accurate diagnoses and prevent misdiagnosis as other neurological conditions.
Observed Findings
- ME/CFS affects approximately one million people in the United States and causes significant morbidity worldwide.
- Current case definitions lack consensus among clinicians and researchers, creating diagnostic uncertainty.
- Symptom overlap exists between ME/CFS and other neurological conditions including early MS and Parkinson's disease.
- Physiological and neurological approaches have been proposed but lack standardization across diagnostic evaluations.
Inferred Conclusions
- Accurate ME/CFS diagnosis requires development of consensus-based case definitions and standardized diagnostic protocols.
- Identification of reliable biomarkers and symptom clustering patterns could improve differential diagnosis and clinical outcomes.
- Longer-term, larger-scale research with appropriate statistical corrections is essential to advance the field.
Remaining Questions
- What specific biomarkers most reliably distinguish ME/CFS from similar conditions like early MS and Parkinson's disease?
- How should core and secondary symptom clusters be formally defined and validated?
- What longitudinal changes in physiological markers occur over the disease course?
What This Study Does Not Prove
This review does not establish any new biomarkers or provide definitive diagnostic criteria for ME/CFS—it synthesizes existing literature and identifies gaps rather than presenting original research data. It does not prove causation for any proposed biological mechanisms, only documents the state of current understanding and areas needing further investigation.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionPainFatigue
Biomarker:NeuroimagingBlood Biomarker
Method Flag:PEM Not DefinedWeak Case Definition